22:51 , Aug 9, 2019 |  BC Extra  |  Company News

BridgeBio looks to fully own its CV subsidiary Eidos

BridgeBio fell $2.94 (10%) to $26.88 Friday after proposing Thursday to fully acquire its cardiovascular-focused subsidiary Eidos, which climbed $3.11 (10%) to $35.17 on the news. BridgeBio Pharma Inc. (NASDAQ:BBIO), which has a 66.6% stake...
04:37 , Aug 1, 2019 |  BC Innovations  |  Distillery Therapeutics

Osteoblast-specific HIVEP3 inhibition to treat osteoporosis

DISEASE CATEGORY: Musculoskeletal INDICATION: Osteoporosis A team led by Guangping Gao, scientific co-founder of gene therapy plays Voyager Therapeutics Inc. and Aspa Therapeutics Inc., showed that an RNAi-based therapy inhibiting HIVEP3 in osteoblasts could treat...
02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
22:58 , Jul 10, 2019 |  BC Extra  |  Company News

Management tracks: Maze, Tiaki, NED, Annexon and more

Maze Therapeutics (Redwood City, Calif.) said Richard Scheller joined its board. Scheller, who in January became chairman of R&D at BridgeBio Pharma Inc. (NASDAQ:BBIO), was CSO and head of therapeutics at personal genetics company 23andMe...
01:21 , Jun 28, 2019 |  BC Extra  |  Financial News

IPO window wide open: BridgeBio leads new listings with year’s largest

Four companies have debuted with upsized NASDAQ offerings in the past 24 hours, including the year's largest, to continue June's torrid IPO pace as 1H19 draws to a close. BridgeBio, Adaptive and Morphic all saw...
00:09 , Jun 27, 2019 |  BC Extra  |  Financial News

June 26 Financial Quick Takes: Adaptive prices upsized IPO; plus BridgeBio, Medicines Co., Global Blood, Odonate

Adaptive raises $300M in IPO  Adaptive Biotechnologies Inc. (NASDAQ:ADPT) raised $300 million through the sale of 15 million shares at $20 in an IPO on NASDAQ. The deal price values the computation immunology and diagnostics...
22:58 , Jun 18, 2019 |  BC Extra  |  Financial News

June 18 Financial Quick Takes: Biohaven sinks on fund-raising news; plus IPO trio sets terms

Amid buyout rumors, Biohaven proposes follow-on  Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) lost $13.54 (24%) to $43.83 on Tuesday, shedding more than half a billion dollars in market cap, after it proposed to raise $300...
00:29 , May 25, 2019 |  BC Extra  |  Financial News

New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero

In a week in which two biotechs went public and a third opted for a billion-dollar takeout instead of an IPO, five companies filed on Friday to list on NASDAQ in IPOs that could raise...
00:26 , Jan 25, 2019 |  BC Week In Review  |  Financial News

BridgeBio raises $299M to advance rare disease portfolio

BridgeBio Pharma LLC (Palo Alto, Calif.) said it raised $299.2 million on Jan. 23 in a venture round to develop compounds for rare genetic diseases. The company in-licenses preclinical and clinical stage assets from academia...
23:35 , Jan 23, 2019 |  BC Extra  |  Financial News

BridgeBio raises $299M to advance rare disease portfolio

BridgeBio Pharma LLC (Palo Alto, Calif.) said it raised $299.2 million on Wednesday in a venture round to develop compounds for rare genetic diseases. The company in-licenses preclinical and clinical stage assets from academia and...